Studies have suggested that KRAS mutations are associated with decreased responsiveness to EGFR-TKIS in NSCLC (16, 46), probably because KRAS mutation can lead to the activation of downstream RAF-MEK-ERK pathway (47). Here, EGFR is linked to non-small cell lung carcinoma.